Literature DB >> 9014757

Rapid recovery of a functional MDR phenotype caused by MRP after a transient exposure to MDR drugs in a revertant human lung cancer cell line.

R Gonzalez Manzano1, C Versanvoort, K Wright, P R Twentyman.   

Abstract

Prior studies have shown that, in some human tumour cells, increased expression of the multidrug resistance gene MDR1 can be induced in response to certain stress conditions such as a transient exposure to cytotoxic agents. Little is known about the possibility of increasing the expression of the recently cloned multidrug resistance-associated protein (MRP) in response to a transient exposure to cytotoxic drugs. In order to examine this possibility, we have used sensitive assays (RT-PCR, flow cytometry) and the sensitive large cell lung cancer cell line, COR-L23/P, and the revertant line (COR-L23/Rev), generated by growing the doxorubicin-selected, MRP-overexpressing resistant variant COR-L23/R without drug exposure for 24-28 weeks. COR-L23/Rev overexpresses MRP, but to a lesser extent than COR-L23/R. COR-L23/Rev rapidly recovered similar levels of MRP mRNA, protein expression, resistance and drug accumulation deficit as COR-L23/R after a 48-72 h exposure to cytotoxic concentrations of doxorubicin or vincristine but not cisplatin. The increase in MRP mRNA could only be detected 3 to 4 days after the transient exposure to drugs. However, when the parental line, COR-L23/P, was exposed to equitoxic doses of doxorubicin, vincristine or cisplatin, no increase in the levels of MRP mRNA could be observed at higher doses (5- to 10-fold the IC50) of doxorubicin or vincristine (but not of cisplatin), we detected a transient increase in the levels of MDR1 mRNA immediately after short-term exposure. In conclusion, we have shown that a human revertant lung cancer cell line (COR-L23/Rev) has the ability to recover quickly, similar levels of MRP expression and resistance as COR-L23/R after a transient exposure to the MDR-drugs doxorubicin and vincristine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9014757     DOI: 10.1016/s0959-8049(96)00263-8

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  3 in total

Review 1.  Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.

Authors:  David J Stewart
Journal:  Crit Rev Oncol Hematol       Date:  2010-01-04       Impact factor: 6.312

2.  Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line.

Authors:  X F Hu; A Slater; D Rischin; P Kantharidis; J D Parkin; J Zalcberg
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

3.  Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines.

Authors:  U Zangemeister-Wittke; T Schenker; G H Luedke; R A Stahel
Journal:  Br J Cancer       Date:  1998-10       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.